EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Radiothérapie et thérapie ciblée pour la prise en charge du cancer du sein : mise au point

A Beddok, P Cottu, A Fourquet, Y Kirova

Cancer/Radiothérapie · 2023

DOI: 10.1016/j.canrad.2023.02.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer/Radiothérapie, 2023. Verfasst von A Beddok und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire d'imagerie translationnelle en oncologie (Lito), Institut Curie, université PSL, université Paris Saclay, Inserm, 91898 Orsay, France; Dé…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 92 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of this study was to review the current knowledge regarding combinations of the most commonly used targeted therapies or those under development for the management of breast cancer with radiation therapy. Several studies have shown that the combination of radiation therapy and tamoxifen increased the risk of radiation-induced lung toxicity; therefore, the two modalities are generally not given concurrently. The combination of HER2 inhibitors (trastuzumab, pertuzumab) and radiation therapy appeared to be safe. However, trastuzumab emtansine (T-DM1) should not be given concomitantly with brain radiation therapy because this combination may increase the risk of brain radionecrosis. The combination of radiation therapy with other new targeted therapies such as new selective estrogen receptor modulators (SERDs), lapatinib, cell cycle inhibitors, immune checkpoint inhibitors, or molecules acting on DNA damage repair seems feasible but has been mainly evaluated on retrospective or prospective studies with small numbers of patients. Moreover, there is a great heterogeneity between these studies regarding the dose and fractionation used in radiotherapy, the dosage of systemic treatments and the sequence of treatments used. Therefore, the combination of these new molecules with radiotherapy should be proposed sparingly, under close monitoring, pending the ongoing prospective studies cited in this review.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsHumansFemaleProspective StudiesRetrospective StudiesTrastuzumabAdo-Trastuzumab EmtansineAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Breast cancerCancer du seinMultimodal treatmentTargeted therapyThérapie cibléeToleranceToléranceTraitement multimodal

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabAdo-Trastuzumab Emtansine

Autor:innen und Institutionen

  • Laboratoire d'imagerie translationnelle en oncologie (Lito), Institut Curie, université PSL, université Paris Saclay, Inserm, 91898 Orsay, France; Département de radiothérapie oncologique, institut Curie, université PSL…
  • Département d'oncologie médicale, institut Curie, Paris, France.
  • Département de radiothérapie oncologique, institut Curie, université PSL, Paris, France.

Zitieren

APA

Beddok, A., Cottu, P., Fourquet, A., & Kirova, Y. (2023). Radiothérapie et thérapie ciblée pour la prise en charge du cancer du sein : mise au point. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2023.02.002

Vancouver

Beddok A, Cottu P, Fourquet A, Kirova Y. Radiothérapie et thérapie ciblée pour la prise en charge du cancer du sein : mise au point. Cancer/Radiothérapie. 2023. doi:10.1016/j.canrad.2023.02.002

BibTeX
@article{Beddok2023,
  author = {Beddok, A and Cottu, P and Fourquet, A and Kirova, Y},
  title = {Radiothérapie et thérapie ciblée pour la prise en charge du cancer du sein : mise au point},
  journal = {Cancer/Radiothérapie},
  year = {2023},
  doi = {10.1016/j.canrad.2023.02.002}
}
Kostenlos starten →